A Study To Investigate The Antidepressant Effect Of Lamotrigine In Patients With Bipolar Disorder Using Lithium
NCT ID: NCT00224510
Last Updated: 2017-05-30
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
120 participants
INTERVENTIONAL
2002-08-31
2006-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Prophylactic Effect of Lamotrigine Compared With Lithium in Bipolar Disorder
NCT00226135
Lamotrigine Phase III Study in Bipolar I Disorder
NCT01602510
Lamotrigine Alone Compared to Lamotrigine Plus Antidepressant for the Treatment of Bipolar II Depression
NCT00475137
Depression And Bipolar Disorder
NCT00274677
Lamictal As Add on Treatment in Mixed States of Bipolar Disorder
NCT00223509
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
lamotrigine
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Currently using lithium.
* Female subjects can't be pregnant or become pregnant during the study.
Exclusion Criteria
* Rapid cyclers.
* Suffering from significant personality disorders.
* Alcohol or substance dependent or abusive.
* Suffering from significant physical conditions.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
GlaxoSmithKline
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
GSK Clinical Trials, MD
Role: STUDY_DIRECTOR
GlaxoSmithKline
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
GSK Investigational Site
Alkmaar, , Netherlands
GSK Investigational Site
Almelo, , Netherlands
GSK Investigational Site
Amersfoort, , Netherlands
GSK Investigational Site
Amsterdam, , Netherlands
GSK Investigational Site
Amsterdam, , Netherlands
GSK Investigational Site
Bennebroek, , Netherlands
GSK Investigational Site
Blaricum, , Netherlands
GSK Investigational Site
Delft, , Netherlands
GSK Investigational Site
Dordrecht, , Netherlands
GSK Investigational Site
Eindhoven, , Netherlands
GSK Investigational Site
Enschede, , Netherlands
GSK Investigational Site
Flushing, , Netherlands
GSK Investigational Site
Gouda, , Netherlands
GSK Investigational Site
Groningen, , Netherlands
GSK Investigational Site
Hoorn, , Netherlands
GSK Investigational Site
Leiden, , Netherlands
GSK Investigational Site
Nijmegen, , Netherlands
GSK Investigational Site
Raalte, , Netherlands
GSK Investigational Site
Retranchement, , Netherlands
GSK Investigational Site
Rosmalen, , Netherlands
GSK Investigational Site
The Hague, , Netherlands
GSK Investigational Site
Tilburg, , Netherlands
GSK Investigational Site
Utrecht, , Netherlands
GSK Investigational Site
Weert, , Netherlands
GSK Investigational Site
Zwolle, , Netherlands
GSK Investigational Site
Alava, , Spain
GSK Investigational Site
Barcelona, , Spain
GSK Investigational Site
Barcelona, , Spain
GSK Investigational Site
Barcelona, , Spain
GSK Investigational Site
Madrid, , Spain
GSK Investigational Site
Valencia, , Spain
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Poster presented at the APA congress, US, 2007 (Lamotrigine as add-on to lithium in bipolar depression) and the 5th European Stanley Conference on Bipolar Disorder in Barcelona, 2006)
van der Loos ML, Mulder PG, Hartong EG, Blom MB, Vergouwen AC, de Keyzer HJ, Notten PJ, Luteijn ML, Timmermans MA, Vieta E, Nolen WA; LamLit Study Group. Efficacy and safety of lamotrigine as add-on treatment to lithium in bipolar depression: a multicenter, double-blind, placebo-controlled trial. J Clin Psychiatry. 2009 Feb;70(2):223-31. doi: 10.4088/jcp.08m04152. Epub 2008 Dec 30.
van der Loos ML, Mulder P, Hartong EG, Blom MB, Vergouwen AC, van Noorden MS, Timmermans MA, Vieta E, Nolen WA; LamLit Study Group. Efficacy and safety of two treatment algorithms in bipolar depression consisting of a combination of lithium, lamotrigine or placebo and paroxetine. Acta Psychiatr Scand. 2010 Sep;122(3):246-54. doi: 10.1111/j.1600-0447.2009.01537.x. Epub 2010 Feb 5.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
SCA30905
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.